Lupin Ltd Q1 FY2024 Concall Summary

Key Takeaways

• Broad-based margin recovery underway: Gross margin hit 63.8% (ex-NCE), up sharply from 55.3% a year ago, driven by U.S. turnaround, India mix, and softer input costs. EBITDA margin guidance of 18%+ exit rate was reaffirmed with confidence.
• U.S. business has turned the corner: Four straight quarters of margin improvement, fueled by stable base portfolio, key product performance, and a pricing environment that has shifted to low-single-digit erosion as industry-wide exits created shortages.
• The pipeline is loaded with near-term catalysts: Spiriva launch is underway, Prolensa and Mirabegron are expected this fiscal year, and the Pithampur clearance unlocks a wave of ophthalmic approvals. Management called out quarter-after-quarter improvement ahead.
• India is back to above-market growth: 11.5% QoQ growth, with core therapies outpacing the market and six new sales divisions beginning to contribute; double-digit full-year growth is the expectation.
• What to watch next quarter: Spiriva substitution ramp and whether the promised sales-force productivity lift in India actually materializes from Q2 onward.

U.S. Generics: The Turnaround Is Now Delivering

• Margin recovery has legs: U.S. margins improved for the fourth consecutive quarter, supported by stable base business, key products (Albuterol, Lisinopril, Suprep), the Darunavir 800 mg exclusivity launch, better product mix, higher price realization on select products, and lower freight and SG&A costs.
• Pricing has stabilized at low-single-digit erosion: Years of brutal price pressure pushed many competitors, including Lupin, out of uneconomical products. The resulting drug shortages have shifted the environment to low-single-digit erosion on the inline portfolio, a dynamic management hopes persists.
• Spiriva is the next material swing factor: Production and shipments began in August; the launch is full-force but generic substitution is expected to ramp gradually, similar to Advair DPI (25-30% building to 40%+). Management hopes to reach fair share (~40% substitution) by the middle of next year and believes no authorized generic is imminent.
• Pithampur clearance unlocks ophthalmic opportunity: The warning letter clearance enables Prolensa (first-to-file, expected this fiscal year) and 3-4 additional ophthalmic products next fiscal year, into a market currently experiencing shortages.
• Mirabegron adds upside late in the year: Expected at the end of this fiscal year with a limited number of day-one players; a new patent suit has been filed but management feels confident about the outcome.

Vinita Gupta: "I think the fact that it had become such a tough environment for the generic industry finally has struck home and has led to this price stabilization, which we hope will continue going forward."

India Business: Core Strength, Sales Force Bet

• Growth rebounded sharply: India recorded 11.5% QoQ and 10.2% YoY growth, overcoming the NLEM impact and the loss of exclusivity on key in-licensed brands like Cidmus. The core business was growing at a healthy rate throughout; the pain was concentrated in the in-license portfolio.
• Therapy leadership is broad: Cardiology and Respiratory grew faster than the market; Diabetes, which had been de-growing due to loss of exclusivity, has returned to growth as planned. Women's Health, GI, and ophthalmic are shaping up; Oncology and CNS are underrepresented and targeted for build-out.
• Sales force expansion is the growth bet: Approximately 1,300 representatives were added in Q3 and Q4 of last year across six new divisions, plus a new extra-urban division. Productivity from these additions is expected to become visible from Q2 onward, supporting consistent above-market growth.
• Patent expiry lumpiness is manageable: Ondero went off patent in August, with much of the impact already reflected in reduced pricing. Another product faces expiry in 2025. Management expects some quarterly lumpiness but not a return to tepid India growth.

Nilesh Gupta: "The primary focus at this point of time has been decluttering, and focusing on building bigger brands. So we're not -- it's not that much of regional expansion at this point of time, but we certainly would hope for more going forward."

Pipeline & Complex Generics: Building the Next Leg

• Spiriva is the immediate catalyst: Launched in Q2; management believes Lupin will be the only generic in the market with no authorized generic imminent, creating a window to drive substitution.
• Injectable ambition is scaling: Nine products were added to the active injectable pipeline this year, spanning 505(j) and 505(b)(2) opportunities. The current pipeline targets ~\$100 million, with an aspiration to build a multi-hundred-million-dollar business over the next five years. Nagpur's FDA approval enables multiple U.S. product approvals from that site.
• Respiratory device platforms are progressing: Significant progress on both Ellipta and Respimat; a material milestone on one Ellipta product is expected by the end of this fiscal year. Green-propellant MDIs are in development for both 505(j) and novel-propellant versions offering differentiation and potential exclusivity.
• Complex injectables and implants advancing: Risperdal Consta trials are complete with filing planned next quarter; approval is expected two-plus years from filing, though management hopes for faster agency engagement given no approved generic exists. Nexplanon and Mirena equivalent versions are actively in the clinic.
• Biosimilars are a steady build: Etanercept commercialization continues with launches in new markets over the next couple of quarters via the Viatris/Biocon partnership. Pegfilgrastim awaits FDA clarity on the Pune site inspection; Ranibizumab is being pursued for the U.S. and through partners into other markets.

Vinita Gupta: "We do have a sizeable build in for building it to a multi-100 million dollar business, but there's still work to be done, to get there."

Margins: Gross Margin Leads, EBITDA Target Reaffirmed

• Gross margin transformation: Gross margin improved from 55.3% in Q1 FY23 to 63.8% ex-NCE income, driven by U.S. margin recovery (from an all-time low last year), India margin improvement, and API margin recovery. Softer API, KSM, chemical, and solvent prices are providing a benefit with a lag effect that will flow through in coming quarters.
• EBITDA margin walk: The 50 bps EBITDA margin improvement was driven by higher gross margin, partially offset by higher R&D expenditure, employee cost from 7.5% global increments, and higher PLI income in the base quarter.
• R&D spend to hold at absolute level: R&D is expected to sustain at the INR 368 cr quarterly level; as a percentage of sales, it should decline as revenue grows. Roughly 20% goes to inhalation, 20% to injectables, and 10% to biosimilars, with more than half directed at complex products.
• Nitrosamine remediation spend is temporary: Consultant and QA testing costs have ramped up to meet FDA guidelines by October/end of this year; these are expected to decline in the second half of the fiscal year and are not sustainable long-term. Management declined to quantify the spend.
• 18%+ exit rate reaffirmed with confidence: Management is sticking to its guidance of an exit rate over 18% in Q4 and a full year above 15%, and is confident of exceeding the Q4 target, citing the current product lineup including Spiriva, cyanocobalamin, diazepam, Prolensa, and Mirabegron.

Ramesh Swaminathan: "What we had said was perhaps in the fourth quarter, you could see an exit rate of over 18%. We're sticking to that, and we are confident of actually exceeding that."

Compliance, API & Other Businesses

• Compliance progress is tangible: Three of five sites under warning letter have now been cleared (Pithampur Unit-2 being the latest). Remediation continues at Tarapur and Mandideep, with no specific timeline given. Nagpur received FDA approval, enabling multiple U.S. product approvals.
• API business is bouncing back: API sales grew 4.5% QoQ and 32.1% YoY, led by recovery in cephalosporin API demand and higher 7ACCA sales. The business had been depressed for two years; further growth will come from new products in the API portfolio. PenG prices remain elevated.
• Emerging markets had a soft quarter: South Africa saw a bumper Q4 ahead of a Q1 price hike, which subdued Q1 results. The Philippines and Mexico had plant issues that are expected to be resolved, though this pattern has persisted over years.
• Fostair is building in Europe: Launched in Germany last month and beginning launches in Italy and other markets through partners. Fiscal year 2025 is expected to be the peak year for Fostair in Europe, where it will represent a meaningful percentage of regional revenues.
• CDMO subsidiary incorporated: Lupin Manufacturing Solutions was set up to undertake contract development and manufacturing activities; management intends to eventually seek external capital for this entity.

Guidance & Commitments

Key Metrics